Vulvovaginal Atrophy Symptoms clinical trials

Explore recruiting vulvovaginal atrophy symptoms clinical trials.

Recruiting vulvovaginal atrophy symptoms studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Vulvovaginal Atrophy Symptoms trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Vaginal administration of selective estrogen receptor modulator (Tamoxifen) treatment to improve sexual function for women with breast cancer. A randomized, double-blinded, placebo controlled longitudinal phase 3 study.

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

Vulvovaginal Atrophy Symptoms trials by city

Vulvovaginal Atrophy Symptoms in Toronto Vulvovaginal Atrophy Symptoms in Vancouver Vulvovaginal Atrophy Symptoms in Montreal Vulvovaginal Atrophy Symptoms in Calgary Vulvovaginal Atrophy Symptoms in Edmonton Vulvovaginal Atrophy Symptoms in Ottawa Vulvovaginal Atrophy Symptoms in Winnipeg Vulvovaginal Atrophy Symptoms in Quebec City Vulvovaginal Atrophy Symptoms in Hamilton Vulvovaginal Atrophy Symptoms in Kitchener Vulvovaginal Atrophy Symptoms in London Vulvovaginal Atrophy Symptoms in Halifax Vulvovaginal Atrophy Symptoms in New York Vulvovaginal Atrophy Symptoms in Los Angeles Vulvovaginal Atrophy Symptoms in Chicago Vulvovaginal Atrophy Symptoms in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease